Abstract
Preventive medicine is appropriate for the majority of patients, including migraine patients, since migraine is considered a chronic condition that causes debilitating headaches that impair quality of life. Oral migraine preventive medications are available, but their use is restricted owing to their side effects and the fact that they are not specifically intended for migraine prevention. The currently available monoclonal antibodies (all have been approved by the Federal Drug Administration (FDA)) were developed specifically for the prevention of migraine and specifically targeted the CGRP peptide, which plays a critical role in the migraine mechanism. Thus, we discussed the breakthrough in migraine prevention in this article, with a particular emphasis on the role of monoclonal antibodies. Keywords: migraine prevention, monoclonal antibodies, CGRP.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
